Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy
Authors
Keywords
-
Journal
HEPATOLOGY RESEARCH
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-05-30
DOI
10.1111/hepr.13196
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
- (2017) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib
- (2017) Tomokazu Kawaoka et al. ONCOLOGY
- Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma
- (2017) Takeshi Terashima et al. Liver Cancer
- Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma
- (2016) Takeshi Terashima et al. BMC CANCER
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis
- (2016) Takeshi Terashima et al. CANCER SCIENCE
- Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study
- (2016) Shuichi Kaneko et al. JOURNAL OF GASTROENTEROLOGY
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma
- (2016) Liver Cancer
- Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives
- (2016) Masatoshi Kudo Liver Cancer
- Prognostic Factors in Patients with Hepatocellular Carcinoma Refractory or Intolerant to Sorafenib
- (2015) Hiroyuki Okuyama et al. ONCOLOGY
- Hepatocellular carcinoma: clinical frontiers and perspectives
- (2014) Jordi Bruix et al. GUT
- Effect of treatment with branched-chain amino acids during sorafenib therapy for unresectable hepatocellular carcinoma
- (2013) Haruhiko Takeda et al. HEPATOLOGY RESEARCH
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
- (2012) T. Pressiani et al. ANNALS OF ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now